Hepatitis B: Treatment, E Antigen, and Immunity Concerns - Gastroenterology and Hepatology

More Info

---

Understanding Hepatitis B, particularly in the context of treatment and the implications of E antigen status, is crucial for managing the disease effectively. Hepatitis B virus (HBV) infection can lead to chronic liver disease, and understanding the serological markers is essential for both treatment decisions and assessing the risk of complications such as liver cirrhosis and hepatocellular carcinoma.


E Antigen and Its Significance
The presence of the Hepatitis B e antigen (HBeAg) indicates active viral replication and a higher level of infectivity. In contrast, the absence of HBeAg (HBeAg negative) often suggests a lower level of viral activity, but this is not always the case. It is important to note that some patients may remain HBeAg positive despite effective antiviral therapy, which can complicate the interpretation of their disease status.

In your case, remaining HBeAg positive while on treatment with tenofovir (惠立妥) suggests that the virus is still replicating, albeit potentially at a lower level than before treatment began. This could be due to several factors, including the possibility of drug resistance, the inherent characteristics of the virus, or the individual’s immune response to the infection.


Treatment Considerations
Tenofovir is a potent antiviral medication with a high barrier to resistance, making it a preferred choice for many patients with chronic Hepatitis B. However, if HBeAg remains positive after a prolonged period of treatment, it may be necessary to evaluate the effectiveness of the therapy. This could involve checking HBV DNA levels to assess viral load, as well as liver function tests to monitor for any signs of liver damage.

If there are concerns about treatment efficacy or if the liver function tests indicate worsening liver function, a liver biopsy may be warranted. A liver biopsy can provide valuable information about the degree of liver inflammation and fibrosis, helping to guide further treatment decisions. However, the need for a biopsy should be carefully considered in the context of your overall health, liver function, and the results of non-invasive tests such as elastography or FibroScan, which can assess liver stiffness and fibrosis without the need for an invasive procedure.


Immunity and Vaccination
Regarding your question about immunity, if you have been diagnosed with chronic Hepatitis B and are HBeAg positive, you are not considered immune to the virus. Immunity typically refers to the presence of antibodies against the virus, specifically the Hepatitis B surface antibody (Anti-HBs). If you have not developed Anti-HBs, it indicates that your body has not successfully cleared the virus or responded adequately to vaccination.

In cases where individuals are at risk of exposure to Hepatitis B (such as healthcare workers or those with potential exposure to infected bodily fluids), vaccination is recommended. However, vaccination is not effective in individuals already infected with the virus. If you have concerns about your immunity or the potential for reinfection, it is advisable to discuss this with your healthcare provider, who can offer personalized recommendations based on your health status.


Conclusion
In summary, remaining HBeAg positive while on tenofovir treatment indicates ongoing viral replication, which may necessitate further evaluation, including potential liver biopsy, to assess liver health and treatment efficacy. Understanding your serological markers and their implications is crucial for managing your Hepatitis B effectively. Regular follow-ups with your healthcare provider are essential to monitor your condition and adjust treatment as necessary. If you have further questions or concerns, do not hesitate to reach out to your healthcare team for guidance tailored to your specific situation.